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Clinicopathological findings in female-to-male gender-affirming breast surgery
Aims: Gender dysphoria is a diagnosis whereby an
individual identifies as the opposite gender. The man-
agement of patients seeking female-to-male (FTM)
transition includes hormonal therapy and surgical
intervention, including mastectomy. The aim of this
study was to characterize the immunohistological
findings in resection specimens from FTM patients.
Methods and results: We reviewed 68 cases (67
patients, one with re-excision) of FTM breast tissue
resection by collecting clinical data, reviewing breast
imaging and pathology reports (gross fibrous density,
specimen weight, and number of cassettes submitted),
and reviewing pathology slides [number of tissue
pieces submitted, number of terminal duct lobule
units (TDLUs), and the presence of histological find-
ings]. Significant histological findings were present in
51 of 68 (75.0%) cases, including one case (1.5%) of
flat epithelial atypia. Fibrocystic changes were the
most common finding (27/68, 39.7%), followed by
gynaecomastoid change, fibrotic stage, (22/68,
32.4%), and fibroadenomatoid change (11/68,
16.2%). Fibrocystic change was associated with
increased numbers of TDLUs, and gynaecomastoid
change was associated with lower body mass index
and decreased numbers of TDLUs. Gynaecomastoid
change showed a moderate proportion of luminal
epithelial cells with strong-intensity immunohisto-
chemical staining for oestrogen receptor, progesterone
receptor, and androgen receptor, and a three-layered
epithelium demonstrated by the use of cytokeratin
5/6 immunohistochemistry.
Conclusions: We identified gynaecomastoid change at
a significantly higher rate than previously reported in
female patients. We support the continued gross and
histological evaluation of FTM specimens in light of
the identification of atypia in one case.
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Introduction
Gender dysphoria is a diagnosis whereby an individ-
ual’s gender identity differs from the external sexual
anatomy at birth.1 The true incidence of gender dys-
phoria remains uncertain. Previous estimates of
prevalence were based on indirect calculations of
those who apply for gender reassignment, receive a
diagnosis of gender dysphoria, start gender-affirma-
tion treatment, and/or apply for legal gender recogni-
tion.2–10 Recent population-based survey methods
have shown that 0.6% of adults (1.4 million individ-
uals) and 0.7% of youths aged 13–17 years
(150 000 individuals) in the USA identify as trans-
gender.11,12 The management of patients seeking
female-to-male (FTM) transition includes hormonal
therapy and surgical intervention.13,14 As patients
are increasingly seeking gender-affirming surgery,
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Michigan Medicine has become a destination centre
for patients seeking surgical intervention for gender
dysphoria.2
Currently, there are limited data in the published
literature on the histological findings in resection
specimens from FTM gender-affirming surgeries. The
most commonly reported changes are fibrosis, atro-
phy, and fibrocystic changes.15 Here, we aim to
provide a comprehensive review of the clinical char-
acteristics, gross findings and immunohistological
features of FTM breast specimens.
Materials and methods
C A S E S E L E C T I O N
Following institutional review board approval, all
cases of FTM transgender affirmation with resection
of breast tissue (1998–2016) were retrieved from
Michigan Medicine Department of Pathology
archives.
C L I N I C A L A N D P A T H O L O G I C A L D A T A
Clinical data, including patient age, body mass index
(BMI), the presence and duration of hormone ther-
apy, smoking history, parity, breast imaging findings,
and family history, were retrieved from medical
records. Specimens had previously undergone gross
and histological evaluation via standard protocols. All
patient pathology reports and slides were available
for review. Pathology reports were reviewed for
weight, gross fibrous density (percentage fibrous tis-
sue), the presence of gross lesions, the number of tis-
sue pieces submitted for microscopic examination,
and the number of cassettes submitted per case. All
haematoxylin and eosin slides were reviewed by two
pathologists (E.G.E. and J.M.J.) for the number of ter-
minal duct lobular units (TDLUs) per case and the
presence of histological findings. TDLUs were scored
as absent if none were present, rare if one to three
were present, and frequent if more than three were
present.
I M M U N O H I S T O C H E M I S T R Y
Immunohistochemical (IHC) staining was performed
on 22 cases with gynaecomastoid change. Commer-
cially available antibodies used were: anti-oestrogen
receptor (ER) (clone SP1, 1:50 dilution; Cell Mar-
que, Rocklin, CA, USA), anti-progesterone receptor
(PR) (clone Y85, 1:40 dilution; Cell Marque), and
anti-androgen receptor (AR) (clone AR441, 1:100
dilution; Thermo-Scientific, Fremont, CA, USA). IHC
staining for cytokeratin (CK) 5/6 was performed on
selected cases (clone D5/16B4; Ventana Medical
Systems, Tucson, AZ, USA). Staining was per-
formed on the Dako Autostainer platform (Agilent
Technologies, Santa Clara, CA, USA), according to
the manufacturer’s instructions, with appropriate
controls.
Oestrogen receptor, PR and AR staining in gynae-
comastoid change was scored by a breast patholo-
gist (J.M.J.), and reported via the Allred scoring
system, with intensity scores (negative, 0; weak, 1;
intermediate, 2; strong, 3) and proportion scores
(none positive, 0; ≤1%, 1; 1–10%, 2; 11–33%, 3;
34–66%, 4; 67–100%, 5) being added to generate a
sum score (with scores of 0–2 being interpreted as
negative and 3–8 as positive. Background
uninvolved (non-gynaecomastoid) glands served as
internal controls.
S T A T I S T I C A L A N A L Y S I S
Descriptive statistics are presented, including continu-
ous data (mean and range) and categorical data (fre-
quency and percentage). A simple logistic regression
model was used to associate clinical, gross and
histopathological findings with gynaecomastoid
change. A multivariate logistic regression model was
generated for the outcome of gynaecomastoid change,
with variables for age, BMI, smoking status, number
of TDLUs, mean gross fibrous density, total specimen
weight, and the use and duration of androgen ther-
apy. Two-way interactions for TDLUs and mean gross
fibrous density, mean gross fibrous density and
androgen use, and mean gross fibrous density and
BMI were included. A stepwise variable selection pro-
cedure was used to select important variables to be
included in final logistic regression model (a signifi-
cance level of 0.35 was used to allow a variable into
the model, and a significance level of 0.20 was used
for a variable to stay in the model). The final model
included BMI and TDLU (0–3). A P-value of ≤0.05
was considered to be statistically significant. All anal-
yses were conducted with SAS (version 9.4; SAS Insti-
tute, Cary, NC, USA).
Results
P A T I E N T S
A total of 68 cases (67 patients with simple mastec-
tomy and free nipple grafting; one with re-excision)
of FTM with breast tissue resection were identified.
© 2017 John Wiley & Sons Ltd, Histopathology, 71, 859–865.
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The mean age at the time of surgery was 31.5 years
(range 19–57 years). Most patients (60/67, 89.6%)
had undergone androgen therapy prior to surgery.
Two patients had undergone pregnancy and child-
birth prior to FTM transition. Family history was
available for 66 (98.5%) patients, and was signifi-
cant for breast cancer in a single relative in 13
(19.7%) patients and for ovarian cancer in a single
relative in one (1.5%) patient. Breast imaging prior
to surgery was infrequent (8/67; 11.9%) (Table 1)
and benign for all patients; for six (75%), the
indication was for routine screening, and for one
(12.5%) there was a palpable lesion for which biopsy
resulted in the diagnosis of fibroadenoma (1; 12.5%
unknown).
G R O S S F I N D I N G S
Specimen weight was recorded in the majority of
cases, and the mean total weight was 1100.2 g. The
mean gross fibrous density was 26.3%. A median of
six (range 2–20) tissue pieces were submitted in a
median of two (range 2–16) cassettes per case. Gross
lesions were infrequently identified (13/68; 19.1%)
(Table 1).
H I S T O L O G I C A L F I N D I N G S
Terminal duct lobule units were absent in 11.8%
(8/68) of cases, rare in 27.9% (19/68), and frequent
in 60.3% (41/68). Diagnostic findings were present
in 75% (51/68) of cases. Fibrocystic changes (27/68;
39.7%) were most frequent (Table 1; Figure 1). Uni-
variate analysis showed fibrocystic changes to be sig-
nificantly associated with the presence of frequent
TDLUs (P = 0.0055).
Gynaecomatoid change was present in 22 (32.4%)
patients, with all cases having features characteristic
of those seen in the fibrotic stage of gynaecomastia of
the male breast, including atrophic duct epithelium
and periductal hyalinization and fibrosis (Figures 1
and 2). Univariate analysis showed gynaecomastoid
change to be significantly associated with younger
age (P = 0.0402), lower BMI (P = 0.0169), increased
gross fibrous density (P = 0.0087), increased total
specimen weight (P = 0.0376), and absent or rare
TDLUs (P = 0.0003). Multivariate analysis showed
gynaecomastoid change to be significantly associated
with absent or rare TDLUs (P = 0.0016) and lower
BMI (P = 0.0087) (Table 2).
No specific histological feature was significantly
associated with gross findings or sampling of greater
numbers of tissue pieces or cassettes.
I M M U N O H I S T O C H E M I S T R Y
Immunohistochemistry staining performed on 22
cases of gynaecomastoid change showed a moderate
proportion of strong-intensity glandular staining for
ER, PR, and AR. Specifically, for ER the median
Allred score was 6, with range of 5–7, for PR the
median Allred score was 6, with range of 4–7, and
for AR the median Allred score was 6, with range of
4–7. The mean AR/ER Allred score ratio was 0.9
(range 0.7–1.0) (Figure 2A–D). CK5/6 IHC staining
performed on eight blocks with gynaecomastoid
change showed positive staining in the outer myo-
epithelial and inner ductal epithelial layers, with no
staining in a discontinuous intermediate epithelial
layer (Figure 2E,F).
Discussion
Here, we present a comprehensive immunomorpho-
logical study of FTM breast resection specimens and
identify features unique to these uncommon speci-
mens. These specimens provide insights into andro-
gen-stimulated breast tissue in a unique patient
population.
Benign breast disease, particularly fibrocystic
change, is a common finding, being identified in up
to 58.5% of asymptomatic women.16,17 In this study,
we identified fibrocystic change in 39.7% of FTM
specimens, which is similar to the proportion noted
by Kuroda et al.18 (60/186; 32.3%). In post-
menopausal women receiving oestrogens for
≥8 years, the prevalence of fibrocystic change is
increased 1.7-fold, supporting a role for increased
oestrogenic states contributing to the development of
fibrocystic change.19 As increased BMI is associated
with an increased oestrogenic state, and TDLU devel-
opment is partially driven by the influence of oestro-
gen, the association of fibrocystic change in FTM
patients with increased BMI and increased numbers
of TDLUs is anticipated.16,20–22
Gynaecomastia-like hyperplasia has been described
as a proliferative lesion of the female breast with his-
tological features typical of gynaecomastia of the
male breast.23,24 However, unlike fibrocystic disease,
the frequent finding of gynaecomastoid change in
32.4% of FTM patients is unusual, considering its
otherwise rare existence in female patients, with pre-
viously reported incidence rates of 0.15% and
0.56%.24,25 In our study, all cases with gynaecomas-
toid change had findings identical to those seen in
the fibrotic stage of male gynaecomastia. Previous
© 2017 John Wiley & Sons Ltd, Histopathology, 71, 859–865.
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studies of FTM breast tissue resection have primarily
noted fibrocystic changes as well as fibrosis and invo-
lutionary changes or lobular atrophy.15,18,26,27 The
fibrotic-stage gynaecomastoid change seen in our
study may be associated with and/or represent an
end-stage histological finding as part of the spectrum
of fibrosis and atrophy described previously.
The majority of FTM patients, including all 22
with gynaecomastoid change, had undergone some
duration of androgen therapy. We did not find a sta-
tistically significant correlation between gynaecomas-
toid change and androgen therapy use or duration.
However, we found gynaecomastoid change to be
significantly associated with lower BMI, which is
probably explained by increased exogenous androgen
and reduced endogenous oestrogen levels, as cross-
sex hormone therapy is known to increase total
body weight and lean body mass in FTM patients.28
In this study, it was difficult to assess overall cumu-
lative doses of exogenous androgens, as some
patients had received these therapies elsewhere, had
intermittent use because of lack of insurance cover-
age, and had variable documentation of dosing in
the available clinical notes. This is a notable limita-
tion of this study, as the degree of androgen expo-
sure is probably a key factor, in addition to BMI,
resulting in gynaecomastoid change in FTM breast
tissue.
In light of the increased prevalence of gynaecomas-
toid change in FTM patients, we sought to compare
the IHC profile with that of male gynaecomastia. Pre-
vious reports have shown that gynaecomastic breast
tissue in male patients expresses receptors for oestra-
diol, progesterone, and androgens,29–32 and has a
characteristic three-layered ductal epithelium with an
outer myoepithelial and two inner epithelial layers.33
Table 1. Clinicopathological features of female-to-male
transgender-affirming patients who underwent resection of
breast tissue (n = 68 unless otherwise stated)
Characteristics Value
Clinical characteristics
Age (years), mean (range) 31.5 (19–57)
BMI, mean (range), n = 66 31.7 (19.2–59.0)
Positive smoking status, n (%), n = 66 5 (7.6)
Androgen therapy, n (%), n = 67 60 (89.6)
Duration (years), mean (range) 1.89 (0.2–10.0)
Prior pregnancy resulting in live birth,
n (%), n = 67
2 (3.0)
Prior breast imaging performed, n (%),
n = 67
8 (11.9)
Family history of breast or ovarian
cancer, n (%), n = 66
14 (21.2)
Non-first degree relative* 13 (19.7)
First-degree relative† 1 (1.5)
Gross characteristics
Total weight (g), mean (range), n = 61 1100.2 (46.5–2890.0)
Fibrous density, mean (range), n = 53 26.3 (3–77.5)
Cassettes submitted, median (range) 2 (2–16)
Total pieces submitted, median
(range), n = 67
6 (2–20)
Number of TDLUs, n (%)
Absent (0) 8 (11.8)
Rare (1–3) 19 (27.9)
Frequent (>3) 41 (60.3)
Gross lesion identified, any type, n (%) 13 (19.1)
Cysts 8 (11.8)
Nodularity 3 (4.4)
Discolouration 2 (2.9)
Histological characteristics, n (%)
Diagnostic finding, any type 51 (75.0)
Fibrocystic changes 27 (39.7)
Simple cysts 22 (32.4)
Apocrine metaplasia 16 (23.5)
Adenosis 5 (7.4)
Usual ductal hyperplasia 3 (4.4)
Table 1. (Continued)
Characteristics Value
Gynaecomastoid change,
fibrotic stage
22 (32.4)
Fibroadenomatoid change 11 (16.2)
Duct ectasia 12 (17.6)
Lactational changes 2 (2.9)
Intraductal papilloma 1 (1.5)
Flat epithelial atypia 1 (1.5)
BMI, Body mass index; TDLU, Terminal duct lobular unit.
*Breast cancer (n = 12), ovarian cancer (n = 1).
†Breast cancer in mother (postmenopausal).
© 2017 John Wiley & Sons Ltd, Histopathology, 71, 859–865.
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A B C
D E F
Figure 1. Histological findings in female-to-male breast resection specimens. A, Flat epithelial atypia. B, Gynaecomastoid change. C,
Fibroadenomatoid change. D, Apocrine metaplasia. E, Simple cysts. F, Duct ectasia.
A B
C D
E F
Figure 2. A–D,
Gynaecomastoid change (A),
with oestrogen receptor (B)
(proportion 3, intensity 3),
progesterone receptor (C)
(proportion 2, intensity 3) and
androgen receptor (D)
(proportion 3, intensity 3)
immunohistochemical staining.
E,F, Gynaecomastoid change
(E), with cytokeratin 5/6
immunohistochemistry
highlighting the outer
myoepithelial and inner ductal
epithelial layers, with no
staining in the intermediate
epithelial layer (F).
© 2017 John Wiley & Sons Ltd, Histopathology, 71, 859–865.
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Benign luminal cells of the breast have been shown
to have scattered, strong positivity for AR in a pat-
tern similar to that for ER, with the majority of those
cells showing dual staining for ER and AR.34 In our
study, gynaecomastoid change showed consistent
positivity for ER and AR in a moderate proportion of
cells with strong intensity of staining, consistent with
that reported previously. Additionally, we noted the
previously reported three-layered staining pattern via
CK 5/6 IHC staining in selected cases with gynaeco-
mastoid change. Overall, the IHC patterns seen in
gynaecomastoid change in FTM patients parallel
those reported in male gynaecomastic tissue.
Our findings support the continued gross and
microscopic evaluation of these unique FTM breast
resection specimens, particularly in light of the pres-
ence of atypia in one case (1.5%). This is similar to
the study by Kuroda et al.,18 who noted atypia in
three (1.6%) and in-situ carcinoma in one (0.5%) of
186 Japanese FTM patients undergoing resection of
breast tissue. Similarly, resection of clinically benign
reduction mammoplasty specimens identified atypia
or carcinoma in 0.16–2.1%.35,36 Ambaye et al.
prospectively evaluated the submission of additional
cassettes of suspicious or fibrous tissue from reduction
mammoplasty specimens, and found improved detec-
tion of atypia and carcinoma in patients aged
>40 years.37 Although the number of cassettes and
number of tissue pieces in our study were not associ-
ated with a particular histological finding, we recom-
mend targeted sampling in multiple areas of gross
fibrous density, as would be performed in other
benign breast specimens.
As noted above, the main limitation of this study is
a lack of data on cumulative androgen exposure.
Additionally, larger future studies would be helpful as
these surgeries become more frequently performed.
Specifically, more data are needed to determine ‘best
practices’ for gross sampling of these specimens, and
to determine features that may aid in identifying
patients at risk for atypical or malignant pathology.
In summary, we have identified unique histological
findings associated with FTM breast resection speci-
mens. Specifically, the relatively frequent finding of
gynaecomastoid change appears to be related to thera-
peutic alteration of the ratio of (exogenous) androgen
and (endogenous) oestrogen in many FTM patients.
Our findings support the continued gross and histologi-
cal evaluation of these uncommon specimens.
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